Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $273.95, for a total transaction of $986,220.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $35,613.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

United Therapeutics Stock Up 0.2 %

United Therapeutics stock traded up $0.51 during trading on Tuesday, reaching $275.76. 599,758 shares of the company’s stock were exchanged, compared to its average volume of 475,352. The company’s 50-day moving average is $255.30 and its two-hundred day moving average is $237.63. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. United Therapeutics Co. has a 52-week low of $208.62 and a 52-week high of $280.30. The firm has a market cap of $12.23 billion, a price-to-earnings ratio of 13.04, a PEG ratio of 4.09 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. During the same period in the prior year, the company earned $4.86 EPS. The firm’s revenue was up 33.7% on a year-over-year basis. On average, analysts predict that United Therapeutics Co. will post 24.61 earnings per share for the current year.

Institutional Trading of United Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in United Therapeutics by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 4,662,911 shares of the biotechnology company’s stock worth $1,053,212,000 after purchasing an additional 20,373 shares during the period. Dimensional Fund Advisors LP boosted its position in United Therapeutics by 1.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 561,950 shares of the biotechnology company’s stock worth $123,566,000 after purchasing an additional 9,962 shares during the period. LSV Asset Management lifted its holdings in United Therapeutics by 40.3% in the 1st quarter. LSV Asset Management now owns 529,519 shares of the biotechnology company’s stock worth $121,641,000 after buying an additional 152,151 shares in the last quarter. Norges Bank acquired a new position in United Therapeutics in the 4th quarter worth $100,519,000. Finally, Swedbank AB acquired a new position in United Therapeutics in the 1st quarter worth $97,316,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

UTHR has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $300.00 target price on shares of United Therapeutics in a research note on Thursday, May 2nd. Wedbush reaffirmed an “outperform” rating and issued a $308.00 target price on shares of United Therapeutics in a research note on Thursday, February 22nd. Oppenheimer lifted their target price on shares of United Therapeutics from $375.00 to $400.00 and gave the stock an “outperform” rating in a research note on Thursday, May 2nd. The Goldman Sachs Group boosted their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a research note on Friday, May 3rd. Finally, StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 4th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $309.44.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.